Eisai Korea Obtains Sales and Marketing Rights for Excegran

Published: 2005-03-10 06:57:00

Updated: 2005-03-10 06:57:00

Eisai Korea and Dong-A Pharmaceutical recently completed an agreement to transfer the domestic sales and marketing rights for anticonvulsant drug Excegran (active ingredient: zonisamide) from Dong-A to Eisai Korea, effective March 1st.

Developed by Dainippon Pharmaceuticals of Japan, Excegran is indicated for use as an adjunctive therapy for treatment of partial seizures in adults with epile...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.